
## Lei Deng

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/440046/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Enhanced radioresponse with a novel recombinant human endostatin protein via tumor vasculature remodeling: Experimental and clinical evidence. Radiotherapy and Oncology, 2013, 106, 130-137.	0.3	28
2	Patterns of recurrence after surgery and efficacy of salvage therapy after recurrence in patients with thoracic esophageal squamous cell carcinoma. BMC Cancer, 2020, 20, 144.	1.1	28
3	Circulating circRNA predicting the occurrence of hepatocellular carcinoma in patients with HBV infection. Journal of Cellular and Molecular Medicine, 2020, 24, 10216-10222.	1.6	26
4	Postoperative Radiotherapy in Pathological T2–3N0M0 Thoracic Esophageal Squamous Cell Carcinoma: Interim Report of a Prospective, Phase III, Randomized Controlled Study. Oncologist, 2020, 25, e701-e708.	1.9	23
5	Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and conventional intensity-modulated radiotherapy in locally advanced non-small-cell lung cancer: a retrospective study. Radiation Oncology, 2019, 14, 106.	1.2	22
6	A phase I/II radiation dose escalation trial using simultaneous integrated boost technique with elective nodal irradiation and concurrent chemotherapy for unresectable esophageal Cancer. Radiation Oncology, 2019, 14, 48.	1.2	20
7	Efficacy and Safety of Combined Brain Radiotherapy and Immunotherapy in Non-Small-Cell Lung Cancer With Brain Metastases: A Systematic Review and Meta-Analysis. Clinical Lung Cancer, 2022, 23, 95-107.	1.1	18
8	Effect of Concurrent Chemoradiation With Celecoxib vs Concurrent Chemoradiation Alone on Survival Among Patients With Non–Small Cell Lung Cancer With and Without Cyclooxygenase 2 Genetic Variants. JAMA Network Open, 2019, 2, e1918070.	2.8	17
9	Clinical outcomes and radiation pneumonitis after concurrent <scp>EGFR</scp> â€tyrosine kinase inhibitors and radiotherapy for unresectable stage <scp>III</scp> nonâ€small cell lung cancer. Thoracic Cancer, 2021, 12, 814-823.	0.8	17
10	MiR-206 suppresses the deterioration of intrahepatic cholangiocarcinoma and promotes sensitivity to chemotherapy by inhibiting interactions with stromal CAFs. International Journal of Biological Sciences, 2022, 18, 43-64.	2.6	14
11	Clinical practice and outcome of radiotherapy for advanced esophageal squamous cell carcinoma between 2002 and 2018 in China: the multi-center 3JECROG Survey. Acta Oncológica, 2021, 60, 627-634.	0.8	13
12	A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer – the 3JECROG P-01 study protocol. BMC Cancer, 2019, 19, 397.	1.1	12
13	The Efficacy of Upfront Intracranial Radiation with TKI Compared to TKI Alone in the NSCLC Patients Harboring EGFR Mutation and Brain Metastases. Journal of Cancer, 2019, 10, 1985-1990.	1.2	11
14	A deep learningâ€based dualâ€omics prediction model for radiation pneumonitis. Medical Physics, 2021, 48, 6247-6256.	1.6	11
15	S-1–Based Chemoradiotherapy Followed by Consolidation Chemotherapy With S-1 in Elderly Patients With Esophageal Squamous Cell Carcinoma: A Multicenter Phase II Trial. Frontiers in Oncology, 2020, 10, 1499.	1.3	9
16	Radiotherapy combined with gefitinib for patients with locally advanced non-small cell lung cancer who are unfit for surgery or concurrent chemoradiotherapy: a phase II clinical trial. Radiation Oncology, 2020, 15, 155.	1.2	9
17	Endostar ( <scp>rhâ€endostatin</scp> ) improves efficacy of concurrent chemoradiotherapy for locally advanced <scp>nonâ€small</scp> cell lung cancer: A systematic review and <scp>metaâ€analysis</scp> . Thoracic Cancer, 2021, 12, 3208-3215.	0.8	9
18	Transcriptome alteration spectrum in rat lung induced by radiotherapy. Scientific Reports, 2019, 9, 19701.	1.6	8

Lei Deng

#	Article	IF	CITATIONS
19	Radiotherapy combined with nimotuzumab for elderly esophageal cancer patients: A phase II clinical trial. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2021, 33, 53-60.	0.7	8
20	A multicenter prospective phase III clinical randomized study of simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal cancer: 3JECROG P-02 study protocol. BMC Cancer, 2020, 20, 901.	1.1	7
21	Efficacy and safety of immune checkpoint inhibitor consolidation after chemoradiation in patients of Asian ethnicity with unresectable stage <scp>III</scp> nonâ€small cell lung cancer: Chinese multicenter report and literature review. Thoracic Cancer, 2020, 11, 2916-2923.	0.8	7
22	Postoperative radiotherapy for pathological stage IIIAâ€N2 nonâ€small cell lung cancer with positive surgical margins. Thoracic Cancer, 2021, 12, 227-234.	0.8	7
23	A validation study on the lung immune prognostic index for prognostic value in patients with locally advanced non–small cell lung cancer. Radiotherapy and Oncology, 2021, 156, 244-250.	0.3	7
24	Treatment planning of volumetric modulated arc therapy and positioning optimization for hippocampalâ€∎voidance prophylactic cranial irradiation. Journal of Applied Clinical Medical Physics, 2021, 22, 15-23.	0.8	6
25	CHST15 promotes the proliferation of TE‑1 cells via multiple pathways in esophageal cancer. Oncology Reports, 2020, 43, 75-86.	1.2	6
26	An East Asian subgroup analysis of PROCLAIM, a phase III trial of pemetrexed and cisplatin or etoposide and cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non–small cell lung cancer. Asia-Pacific Journal of Clinical Oncology, 2016, 12, 380-387.	0.7	5
27	Silence of S1 RNA binding domain 1 represses cell growth and promotes apoptosis in human non-small cell lung cancer cells. Translational Lung Cancer Research, 2019, 8, 760-774.	1.3	5
28	Impact of thoracic radiation therapy after chemotherapy on survival in extensiveâ€stage small cell lung cancer: A propensity scoreâ€matched analysis. Thoracic Cancer, 2019, 10, 799-806.	0.8	4
29	Concurrent chemoradiotherapy versus radiotherapy alone for patients with locally advanced esophageal squamous cell carcinoma in the era of intensity modulated radiotherapy: a propensity scoreâ€matched analysis. Thoracic Cancer, 2021, 12, 1831-1840.	0.8	4
30	Adjuvant treatment may benefit patients with high-risk upper rectal cancer: A nomogram and recursive partitioning analysis of 547 patients. Oncotarget, 2016, 7, 66160-66169.	0.8	4
31	A Nomogram for Predicting Brain Metastasis in IIIA-N2 Non-Small Cell Lung Cancer After Complete Resection: A Competing Risk Analysis. Frontiers in Oncology, 2021, 11, 781340.	1.3	4
32	Chemoradiotherapy is an alternative choice for patients with primary mediastinal seminoma. Radiation Oncology, 2022, 17, 58.	1.2	4
33	Development and validation of a prediction model using molecular marker for longâ€ŧerm survival in unresectable stage <scp>III</scp> nonâ€small cell lung cancer treated with chemoradiotherapy. Thoracic Cancer, 2022, 13, 296-307.	0.8	4
34	Radiation pneumonitis complicated by <i>Pneumocystis carinii</i> in patients with thoracic neoplasia: a clinical analysis of 7 cases. Cancer Communications, 2019, 39, 1-4.	3.7	3
35	A Phase II Trial of Concurrent Temozolomide and Hypofractionated Stereotactic Radiotherapy for Complex Brain Metastases. Oncologist, 2019, 24, e914-e920.	1.9	3
36	The Sequence of Intracranial Radiotherapy and Systemic Treatment With Tyrosine Kinase Inhibitors for Gene-Driven Non-Small Cell Lung Cancer Brain Metastases in the Targeted Treatment Era: A 10-Year Single-Center Experience. Frontiers in Oncology, 2021, 11, 732883.	1.3	3

Lei Deng

#	Article	IF	CITATIONS
37	Local Therapy Combined With First-Line EGFR Tyrosine Kinase Inhibitor Achieves Favorable Survival in Patients With EGFR-Mutant Metastatic Non-Small Cell Lung Cancer. Clinical Medicine Insights: Oncology, 2022, 16, 117955492210803.	0.6	2
38	Modified Glasgow prognostic score predicts the prognosis of patients with advanced esophageal squamous cell carcinoma: A propensity scoreâ€matched analysis. Thoracic Cancer, 2022, 13, 2041-2049.	0.8	2
39	Salvage chemoradiation therapy for recurrence after radical surgery or palliative surgery in esophageal cancer patients: a prospective, multicenter clinical trial protocol. BMC Cancer, 2020, 20, 877.	1.1	1
40	Prospective Exploratory Study of the Clinical Significance of Circulating Tumor Cells in Patients With Small Cell Lung Cancer Exposed to Prophylactic Cranial Irradiation. Frontiers in Oncology, 2020, 10, 575394.	1.3	1
41	Definitive Simultaneous Integrated Boost Versus Conventional-Fractionated Intensity Modulated Radiotherapy for Patients With Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Analysis. Frontiers in Oncology, 2021, 11, 618776.	1.3	1
42	Possible contribution of IMRT in postoperative radiochemotherapy for rectal cancer: analysis on 1798 patients by prediction model. Oncotarget, 2016, 7, 46536-46544.	0.8	1
43	Clinical significance of ALDH1A1 expression and its association with E-cadherin and N-cadherin in resected large cell neuroendocrine carcinoma. Translational Oncology, 2022, 19, 101379.	1.7	1
44	Conditional <scp>catheterâ€related</scp> thrombosis free probability and riskâ€adapted choices of catheter for lung cancer. Thoracic Cancer, 2022, , .	0.8	1
45	Factors affecting the completion of concurrent chemotherapy and impact of non-completion on survival in locally advanced esophageal squamous cell carcinoma. Esophagus, 0, , .	1.0	1
46	The mutational profile analysis of different response to neoadjuvant chemoradiation therapy in local advanced esophageal squamous cell cancer patients Journal of Clinical Oncology, 2019, 37, e15560-e15560.	0.8	0